Moderna

MRNA
1.8
Companies list

Public Statements Risk

3

Due to the COVID-19 Pandemic, Moderna is a high profile company yet is receding from the spotlight. CEO, Stephane Bacel, does not have a big social media footprint, but often appears in interviews and article mentions. In 2023, Bernie Sanders and Bacel were battling over how much Moderna owes the government for COVID-19 vaccination costs and the associated R&D expenses. Overall, the government backs the vaccination but not the company. Noubar Afeyan, a co-founder, made comments in 2023 against Texas banning the abortion pill, which generated some press. The company's site includes sections on DEI and environmental sustainability, linked to from the header.

Political Contributions Risk

1

Moderna contributes with a substantial Democratic skew coming entirely from senior executives. When compared to the Healthcare sector as a whole, Moderna is one of the smallest contributors, with a minimal level of giving. Previous donations to controversial political figure Hillary Clinton increase risk. The brand's partisanship is significant but when benchmarked to sector and considered within the context of the negligible contribution size, the overall political giving risk is low.

Political Dichotomy Risk

1

Moderna, like the rest of the pharmaceutical industry, has a Democratic skew in terms of political contributions, although it donates far less than its competitors. Moderna, like Biogen, is mainly B2B and relies on other corporations to deliver their products to individual consumers. Because of this, the brand's corporate customers are more likely to focus on economic rather than political factors.

Associational Risk

3

After Moderna hiked prices for COVID-19 vaccines, Bernie Sanders criticized the company and CEO Stephane Bacel. The relationship between Biden and Moderna is complicated by recent clashes sorrounding price hikes, prompting officials in the Biden administration to publicly complain about difficulties related to working with the BioTech giant. Finally, there seems to be a relationship between Governor DeSantis and Moderna through the company's lobbyist Marc Lampkin who has hosted a DeSantis fundraiser.

Brand Visibility Risk

2

Post-COVID, Moderna has incredibly high brand recognition, but is a biotech company, so it remains extremely well insulated.

Moderna

MRNA
1.8
Companies list

Public Statements Risk

3

Due to the COVID-19 Pandemic, Moderna is a high profile company yet is receding from the spotlight. CEO, Stephane Bacel, does not have a big social media footprint, but often appears in interviews and article mentions. In 2023, Bernie Sanders and Bacel were battling over how much Moderna owes the government for COVID-19 vaccination costs and the associated R&D expenses. Overall, the government backs the vaccination but not the company. Noubar Afeyan, a co-founder, made comments in 2023 against Texas banning the abortion pill, which generated some press. The company's site includes sections on DEI and environmental sustainability, linked to from the header.

Political Contributions Risk

1

Moderna contributes with a substantial Democratic skew coming entirely from senior executives. When compared to the Healthcare sector as a whole, Moderna is one of the smallest contributors, with a minimal level of giving. Previous donations to controversial political figure Hillary Clinton increase risk. The brand's partisanship is significant but when benchmarked to sector and considered within the context of the negligible contribution size, the overall political giving risk is low.

Political Dichotomy Risk

1

Moderna, like the rest of the pharmaceutical industry, has a Democratic skew in terms of political contributions, although it donates far less than its competitors. Moderna, like Biogen, is mainly B2B and relies on other corporations to deliver their products to individual consumers. Because of this, the brand's corporate customers are more likely to focus on economic rather than political factors.

Associational Risk

3

After Moderna hiked prices for COVID-19 vaccines, Bernie Sanders criticized the company and CEO Stephane Bacel. The relationship between Biden and Moderna is complicated by recent clashes sorrounding price hikes, prompting officials in the Biden administration to publicly complain about difficulties related to working with the BioTech giant. Finally, there seems to be a relationship between Governor DeSantis and Moderna through the company's lobbyist Marc Lampkin who has hosted a DeSantis fundraiser.

Brand Visibility Risk

2

Post-COVID, Moderna has incredibly high brand recognition, but is a biotech company, so it remains extremely well insulated.

Moderna

MRNA
1.8
Companies list

Public Statements Risk

3

Due to the COVID-19 Pandemic, Moderna is a high profile company yet is receding from the spotlight. CEO, Stephane Bacel, does not have a big social media footprint, but often appears in interviews and article mentions. In 2023, Bernie Sanders and Bacel were battling over how much Moderna owes the government for COVID-19 vaccination costs and the associated R&D expenses. Overall, the government backs the vaccination but not the company. Noubar Afeyan, a co-founder, made comments in 2023 against Texas banning the abortion pill, which generated some press. The company's site includes sections on DEI and environmental sustainability, linked to from the header.

Political Contributions Risk

1

Moderna contributes with a substantial Democratic skew coming entirely from senior executives. When compared to the Healthcare sector as a whole, Moderna is one of the smallest contributors, with a minimal level of giving. Previous donations to controversial political figure Hillary Clinton increase risk. The brand's partisanship is significant but when benchmarked to sector and considered within the context of the negligible contribution size, the overall political giving risk is low.

Political Dichotomy Risk

1

Moderna, like the rest of the pharmaceutical industry, has a Democratic skew in terms of political contributions, although it donates far less than its competitors. Moderna, like Biogen, is mainly B2B and relies on other corporations to deliver their products to individual consumers. Because of this, the brand's corporate customers are more likely to focus on economic rather than political factors.

Associational Risk

3

After Moderna hiked prices for COVID-19 vaccines, Bernie Sanders criticized the company and CEO Stephane Bacel. The relationship between Biden and Moderna is complicated by recent clashes sorrounding price hikes, prompting officials in the Biden administration to publicly complain about difficulties related to working with the BioTech giant. Finally, there seems to be a relationship between Governor DeSantis and Moderna through the company's lobbyist Marc Lampkin who has hosted a DeSantis fundraiser.

Brand Visibility Risk

2

Post-COVID, Moderna has incredibly high brand recognition, but is a biotech company, so it remains extremely well insulated.

Moderna

MRNA
1.8
Companies list

Public Statements Risk

3

Due to the COVID-19 Pandemic, Moderna is a high profile company yet is receding from the spotlight. CEO, Stephane Bacel, does not have a big social media footprint, but often appears in interviews and article mentions. In 2023, Bernie Sanders and Bacel were battling over how much Moderna owes the government for COVID-19 vaccination costs and the associated R&D expenses. Overall, the government backs the vaccination but not the company. Noubar Afeyan, a co-founder, made comments in 2023 against Texas banning the abortion pill, which generated some press. The company's site includes sections on DEI and environmental sustainability, linked to from the header.

Political Contributions Risk

1

Moderna contributes with a substantial Democratic skew coming entirely from senior executives. When compared to the Healthcare sector as a whole, Moderna is one of the smallest contributors, with a minimal level of giving. Previous donations to controversial political figure Hillary Clinton increase risk. The brand's partisanship is significant but when benchmarked to sector and considered within the context of the negligible contribution size, the overall political giving risk is low.

Political Dichotomy Risk

1

Moderna, like the rest of the pharmaceutical industry, has a Democratic skew in terms of political contributions, although it donates far less than its competitors. Moderna, like Biogen, is mainly B2B and relies on other corporations to deliver their products to individual consumers. Because of this, the brand's corporate customers are more likely to focus on economic rather than political factors.

Associational Risk

3

After Moderna hiked prices for COVID-19 vaccines, Bernie Sanders criticized the company and CEO Stephane Bacel. The relationship between Biden and Moderna is complicated by recent clashes sorrounding price hikes, prompting officials in the Biden administration to publicly complain about difficulties related to working with the BioTech giant. Finally, there seems to be a relationship between Governor DeSantis and Moderna through the company's lobbyist Marc Lampkin who has hosted a DeSantis fundraiser.

Brand Visibility Risk

2

Post-COVID, Moderna has incredibly high brand recognition, but is a biotech company, so it remains extremely well insulated.

Moderna

MRNA
1.8
Companies list

Public Statements Risk

3

Due to the COVID-19 Pandemic, Moderna is a high profile company yet is receding from the spotlight. CEO, Stephane Bacel, does not have a big social media footprint, but often appears in interviews and article mentions. In 2023, Bernie Sanders and Bacel were battling over how much Moderna owes the government for COVID-19 vaccination costs and the associated R&D expenses. Overall, the government backs the vaccination but not the company. Noubar Afeyan, a co-founder, made comments in 2023 against Texas banning the abortion pill, which generated some press. The company's site includes sections on DEI and environmental sustainability, linked to from the header.

Political Contributions Risk

1

Moderna contributes with a substantial Democratic skew coming entirely from senior executives. When compared to the Healthcare sector as a whole, Moderna is one of the smallest contributors, with a minimal level of giving. Previous donations to controversial political figure Hillary Clinton increase risk. The brand's partisanship is significant but when benchmarked to sector and considered within the context of the negligible contribution size, the overall political giving risk is low.

Political Dichotomy Risk

1

Moderna, like the rest of the pharmaceutical industry, has a Democratic skew in terms of political contributions, although it donates far less than its competitors. Moderna, like Biogen, is mainly B2B and relies on other corporations to deliver their products to individual consumers. Because of this, the brand's corporate customers are more likely to focus on economic rather than political factors.

Associational Risk

3

After Moderna hiked prices for COVID-19 vaccines, Bernie Sanders criticized the company and CEO Stephane Bacel. The relationship between Biden and Moderna is complicated by recent clashes sorrounding price hikes, prompting officials in the Biden administration to publicly complain about difficulties related to working with the BioTech giant. Finally, there seems to be a relationship between Governor DeSantis and Moderna through the company's lobbyist Marc Lampkin who has hosted a DeSantis fundraiser.

Brand Visibility Risk

2

Post-COVID, Moderna has incredibly high brand recognition, but is a biotech company, so it remains extremely well insulated.

See this company on INDEXALIGN